Eli Lilly has become the proud owner of ImClone, successfully outbidding Bristol-Myers Squibb (BMS) and paying nearly US$2 B more than BMS’ original offer in the process. ImClone fitted neatly into both companies’ strategies, though the size of this acquisition shows that Eli Lilly was the more eager out of the two. ImClone does, however, come with some strings attached.